RxDoctor Payments Data

Mamta Jain, MD

Internal Medicine · The Woodlands, TXNPI 1528138419

Payments from drug & device makers

$3,410in general payments, 2019–2025

Across 173 payments — averaging $19.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$963
  • Boston Scientific$389
  • Lilly USA, LLC$242
  • Johnson & Johnson$237
  • Novo Nordisk$226
  • GSK$211
  • plus $1K from 19 others

What the payments were for

  • Food & beverage$3,410100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$3,410 in reported general payments places this provider in the 80th percentile of 7,675 internal medicine providers in Texas.

See all internal medicine providers in Texas

Medicare billing

Part B allowed, 2024
$223,871
Medicare patients
166
Services billed
2,360

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol132$157,109
Trelegy ElliptaFluticasone/Umeclidin/Vilanter91$104,731
OzempicSemaglutide67$102,889
JardianceEmpagliflozin59$82,168
RybelsusSemaglutide21$36,950
Soliqua 100-33Insulin Glargine/Lixisenatide12$20,997
Breztri AerosphereBudesonide/Glycopyr/Formoterol21$17,631
Tresiba Flextouch U-100Insulin Degludec13$11,759
DapagliflozinDapagliflozin Propanediol13$10,758
Nebivolol Hcl84$6,195
Rosuvastatin Calcium453$5,568
Liothyronine Sodium176$5,098
Levothyroxine Sodium275$2,919
Fluticasone-SalmeterolFluticasone Propion/Salmeterol11$2,871
Olmesartan Medoxomil146$2,468

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Breztri Aerosphere$963$174,740153 claims
Novo NordiskOzempic, Rybelsus$226$139,83988 claims
GSKTrelegy Ellipta$211$104,73191 claims
Boehringer IngelheimJardiance$138$82,16859 claims
Sanofi-aventis U.S. LLCSoliqua 100-33$12$20,99712 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 7,675 internal medicine providers in Texas.

Other internal medicine in The Woodlands

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →